drugset / Trial / NCT00492440

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

NCT00492440

Phase 1 Terminated 9 enrolled Cytheris SA
Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Interleukin-7 may stimulate the white blood cells to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally advanced or metastatic kidney cancer.

Timeline

Start
2007-05
Primary completion
2010-07
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Interleukin-7 Protein / enzyme biologic Subcutaneous